Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Antios Raises $96m To Advance HBV Drug With Pharmasset Pedigree

Apr 12 2021

• By Joseph Haas

Hepatitis B — With $96m, Antios will continue developing ATI-2173 toward functional cure in HBV

Related Content

Gilead Buys Triangle; Viread/Coviracil Fixed-Dose Combo Launch Set For 2005

Dec 09 2002

It’s “Full Speed Ahead” For Merck In HCV After $3.85B Idenix Buyout

Jun 09 2014

In Hep B, Functional Cure Likely Means Two-Part Combination Process

Nov 23 2017

Hep B Cure May Lie In Reducing Surface Antigen

Apr 28 2017

Finance Watch: Alternative Funding Sources Crucial Even Amidst A Biopharma VC Boom

Dec 17 2018

Gilead HCV Sales Plateau, But Maintain Dominant Market Share

Oct 28 2015

Related Companies

Pharmasset, Inc.

Bukwang Pharmaceutical Co., Ltd.

Gilead Sciences, Inc.

Triangle Pharmaceuticals Inc.

Emory University

Idenix Pharmaceuticals, Inc.

Merck & Co., Inc.

Johnson & Johnson

Arbutus Biopharma Corporation

Arrowhead Pharmaceuticals, Inc.

Bristol Myers Squibb Company

Additional Topics

Financing Business Strategies Companies Commercial Infectious Diseases BioPharmaceutical

More from Financing

More from Business

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.